Glatiramer Acetate
PM030
Phase 3 small_molecule completed
Quick answer
Glatiramer Acetate for Optic Neuritis is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Optic Neuritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed